Q-omics provides the consensus-scored ASMTL profile across patient tissues and cancer cell-line models. ASMTL expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ASMTL is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, ASMTL protein abundance shows 17,221 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, KICH, and HNSC as cancer lineages where ASMTL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASMTL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASMTL survival associations across molecular data types. ASMTL RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASMTL RNA expression–survival associations across cancer types. High ASMTL expression shows unfavorable associations in BLCA, but favorable associations in KIRC, UVM, SKCM, OV and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ASMTL RNA expression.
This table summarizes ASMTL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ASMTL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASMTL shows lower tumor expression in KICH, BLCA, KIRP, UCEC and BRCA and higher tumor expression in LIHC. The KICH box plot shows higher ASMTL RNA expression in normal versus tumor tissue (log2 FC = −1.476, t-test p < 0.001).
This table shows molecular features associated with ASMTL in patient tissues and cancer cell lines. In patient samples, ASMTL shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, ASMTL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
